Biocidal Products on Muck Rack

Biocidal Products

As seen in: The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Biocidal

Contact Biocidal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab

|
By Lorenzo Guizzaro, Marion Haberkamp, Biocidal Products
| The Lancet Verified
Keywords Dementia Donanemab Lecanemab EMA approvals Alzheimer's disease Introduction Alzheimer's disease (AD) is the leading cause of dementia, affecting nearly 8 million people in the European Union as of 2021,1 and this number is increasing.2 It is reported as the most feared disease for people over the age of 503 and, despite decades of research, treatments that slow down the progression of AD have proven elusive.4 Patients with AD go through a pre-symptomatic phase where pathological...
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified